Enodia Therapeutics Secures €20.7M Seed Funding to Advance Novel Protein Degradation Platform Targeting SEC61 Translocon
Key Insights
Enodia Therapeutics (search) raised €20.7 million in seed financing co-led by Elaia (search), Pfizer Ventures (search), and Bpifrance (search) to develop small-molecule therapies (search) for targeted protein degradation.
The company's proprietary platform uses machine learning to selectively modulate the SEC61 translocon (search), intervening at the point of protein synthesis rather than after proteins are fully formed.
Enodia plans to advance its lead program toward preclinical candidate selection within the next year, initially focusing on inflammatory and autoimmune diseases (search).
Enodia Therapeutics (search) has secured €20.7 million (US$25 million) in seed financing to advance its novel small-molecule platform for targeted protein degradation. The round was co-led by Elaia (search), Pfizer Ventures (search), and Bpifrance (search) as part of the InnoBio investment strategy, with participation from Wallonie Entreprendre, MACSF, Institut Pasteur, InvestSud, Sambrinvest, and Mission BioCapital, alongside founding investor Argobio Studio (search).
The biotechnology company, founded by Argobio Studio (search) based on pioneering research from Institut Pasteur, is developing a unique approach to protein degradation that intervenes at the point of protein synthesis rather than targeting fully formed proteins. This strategy aims to prevent disease-driving proteins from ever reaching maturity and causing cellular damage.
Revolutionary Approach to Protein Degradation
Enodia's proprietary discovery platform centers on the selective modulation of the SEC61 translocon (search), a critical gateway through which newly formed proteins enter the endoplasmic reticulum. The company uses machine learning to design small-molecule therapies (search) that eliminate pathogenic proteins as they are produced, representing a significant departure from conventional protein-degrading drugs.
"By integrating machine learning and proteomics-driven insight with signal-peptide informed discovery, we can develop potentially best-in-class small molecules targeting SEC61, identifying truly selective therapeutic candidates for high-unmet-need conditions, with an initial focus on inflammatory and autoimmune diseases (search)," said Yves Ribeill, Chief Executive Officer of Enodia Therapeutics (search).
The platform leverages a large chemical space spanning several families of well-characterized inhibitors, combined with a tailored library of signal-peptide cell lines. The company integrates machine-learning-driven selectivity, proteomics-based secretome analysis, and structural validation to guide rational drug design, enabling access to previously undruggable secreted and membrane protein targets.
Targeting Previously Undruggable Biology
The SEC61 translocon (search) was considered an undruggable target until recent years due to its intricate biology. According to Ribeill, "While the Sec61 biology was discovered some time ago, the fine understanding of the mode of action was established in the last 3 to 4 years with the publication of crystallographic data of the complex. Enodia's platform uses these latest data to enable new level of selectivity."
Many pathogenic proteins, particularly those involved in cancer (search), inflammation, and autoimmune disorders, depend on the SEC61 pathway to be properly folded and transported to their site of action. By selectively disrupting this process, Enodia aims to prevent harmful proteins from reaching maturity without compromising vital physiological functions.
Competitive Landscape and Differentiation
Enodia enters a rapidly evolving protein degradation field where several companies are pursuing similar mechanisms. Gate Bio (search) recently completed a $65 million Series B round to advance small molecule drugs that eliminate target proteins by blocking progress through the SEC61 secretory channel, and has secured a deal worth up to $856 million with Eli Lilly.
However, Enodia differentiates itself through its selective approach. While competitors like Kezar Life Sciences developed non-selective SEC61 inhibitors (search), Ribeill noted, "Our strategy at Enodia is to develop selective inhibitors of Sec-61 targeting pathogenic proteins."
Development Timeline and Strategic Vision
The newly raised capital will advance Enodia's lead program toward preclinical candidate selection, a milestone expected within the next year that will represent a major inflection point for the company. This achievement will lay the groundwork for subsequent IND-enabling studies and future clinical development.
"We are well positioned to progress our lead program to preclinical candidate selection over the coming year, representing an important value inflection point for Enodia," said Ribeill, who also served as Entrepreneur in Residence at Argobio during the company's inception.
The company is initially focusing on inflammatory and autoimmune diseases (search), with additional opportunities across oncology and viral infections (search) enabled by the same underlying biological mechanism.
Argobio Studio's Venture Building Success
Enodia represents the third company founded by Argobio Studio (search) to achieve seed financing in 2025, following Elkedonia's €11.25 million round in June for first-in-class antidepressant candidates and Laigo Bio's €11.5 million financing in December for its SureTAC precision membrane protein degradation platform.
"Enodia is the third of eight companies created by Argobio to achieve seed financing, underscoring the strength and consistency of our studio model," said Daniel Sobral, Chief Financial Officer and Head of Corporate Development at Argobio. "Our operational venture-building approach is designed to rapidly translate Europe's leading scientific innovation into globally competitive biotech companies."
Bpifrance (search)'s participation through its InnoBio investment strategy reflects the fund's commitment to nurturing French life sciences innovation. Launched in 2009, the €173 million InnoBio fund specializes in early- and mid-stage biotechnology and MedTech companies, supporting them through critical growth phases across oncology, rare diseases, cardiovascular and metabolic disorders, neurology, ophthalmology, and infectious and inflammatory diseases (search).